Yinnugo

Yinnugo is a Human Normal Immunoglobulin solution for intravenous use, derived from human plasma. It supports immune function by providing a broad spectrum of antibodies. This therapy is used for immune deficiencies and certain autoimmune conditions. Suitable for patients requiring immunoglobulin replacement.

Human Normal Immunoglobulin, like Yinnugo, is used to treat primary immune deficiencies where the body lacks sufficient antibodies. It may also be used for secondary immunodeficiencies, such as those caused by HIV or chemotherapy. Additionally, it supports patients with certain autoimmune disorders by modulating immune responses. This therapy helps maintain immune function in individuals with weakened immune systems.

Yinnugo provides passive immunity by supplying a concentrated mix of antibodies from healthy donors. These antibodies help the body recognize and respond to infections more effectively. Patients may experience improved resistance to common illnesses and reduced frequency of infections. The effects are typically observed as enhanced immune defense over time.

Yinnugo should be administered under medical supervision due to potential risks like allergic reactions. Patients with a history of severe hypersensitivity to immunoglobulins should avoid this therapy. Regular monitoring is recommended to assess tolerance and effectiveness. Ensure proper storage conditions are maintained to preserve the product's integrity.

Concurrent use of live vaccines may reduce their effectiveness when administered alongside Yinnugo. Immunoglobulins can interact with certain medications, including those affecting the immune system. Patients should inform healthcare providers about all current medications. Avoid mixing with other intravenous solutions unless approved by a medical professional.